Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Langer

Showing results (171-180 of 199) with videos related to

Pageof 20
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 10, 2020
<sup>18</sup>F-FLT PET/CT Adds Value to <sup>18</sup>F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical TrialTine Nøhr Christensen, Seppo W Langer, Gitte Persson, et al.
Lung Cancer (Amsterdam, Netherlands)|February 20, 2022
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancerKristin Toftaker Killingberg, Tarje Onsøien Halvorsen, Øystein Fløtten, et al.
Integrative Cancer Therapies|October 5, 2016
Changes in Health-Related Quality of Life During Rehabilitation in Patients With Operable Lung Cancer: A Feasibility Study (PROLUCA)Maja S Sommer, Karen Trier, Jette Vibe-Petersen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 24, 2020
<sup>64</sup>Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After InjectionMathias Loft, Esben A Carlsen, Camilla B Johnbeck, et al.
Acta Oncologica (Stockholm, Sweden)|August 21, 2014
Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasmsEva Tiensuu Janson, Halfdan Sorbye, Staffan Welin, et al.
Acta Oncologica (Stockholm, Sweden)|May 17, 2021
Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasmsEva Tiensuu Janson, Ulrich Knigge, Gitte Dam, et al.
Annals of Hematology|February 9, 2000
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)A Ganser, G Heil, G Seipelt, et al.
The Journal of Clinical Endocrinology and Metabolism|August 2, 2019
Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for InsulinomaMikkel Andreassen, Emma Ilett, Dominik Wiese, et al.
Diagnostics (Basel, Switzerland)|March 29, 2019
Very Early Response Evaluation by PET/MR in Patients with Lung Cancer-Timing and FeasibilityNatasha Hemicke Langer, Seppo W Langer, Helle Hjorth Johannesen, et al.
British Journal of Cancer|October 23, 2023
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasmsSiren Morken, Seppo W Langer, Anna Sundlöv, et al.
Pageof 20

Showing results (171-180 of 199) with videos related to

Sort By:
Pageof 20
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 10, 2020
<sup>18</sup>F-FLT PET/CT Adds Value to <sup>18</sup>F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical TrialTine Nøhr Christensen, Seppo W Langer, Gitte Persson, et al.
Lung Cancer (Amsterdam, Netherlands)|February 20, 2022
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancerKristin Toftaker Killingberg, Tarje Onsøien Halvorsen, Øystein Fløtten, et al.
Integrative Cancer Therapies|October 5, 2016
Changes in Health-Related Quality of Life During Rehabilitation in Patients With Operable Lung Cancer: A Feasibility Study (PROLUCA)Maja S Sommer, Karen Trier, Jette Vibe-Petersen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 24, 2020
<sup>64</sup>Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After InjectionMathias Loft, Esben A Carlsen, Camilla B Johnbeck, et al.
Acta Oncologica (Stockholm, Sweden)|August 21, 2014
Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasmsEva Tiensuu Janson, Halfdan Sorbye, Staffan Welin, et al.
Acta Oncologica (Stockholm, Sweden)|May 17, 2021
Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasmsEva Tiensuu Janson, Ulrich Knigge, Gitte Dam, et al.
Annals of Hematology|February 9, 2000
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)A Ganser, G Heil, G Seipelt, et al.
The Journal of Clinical Endocrinology and Metabolism|August 2, 2019
Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for InsulinomaMikkel Andreassen, Emma Ilett, Dominik Wiese, et al.
Diagnostics (Basel, Switzerland)|March 29, 2019
Very Early Response Evaluation by PET/MR in Patients with Lung Cancer-Timing and FeasibilityNatasha Hemicke Langer, Seppo W Langer, Helle Hjorth Johannesen, et al.
British Journal of Cancer|October 23, 2023
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasmsSiren Morken, Seppo W Langer, Anna Sundlöv, et al.
Pageof 20